

THE PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY

Author Index to Volume 5: January 2003 Through December 2003

- Adams S.** Review of Lilienfeld SO, Lynn SJ, Lohr JM (eds): *Science and Pseudoscience in Clinical Psychology*. 94
- Barkin RL** see **Leo RJ**
- Berg JE.** Mortality and return to work of drug abusers from therapeutic community treatment 3 years after entry. 164–168
- Berigan TR.** Panic attacks during escalation of mirtazapine [letter]. 93
- Berigan TR.** Tiagabine in the treatment of nervios [letter]. 49
- Bobo WV, More KF.** Potential association between risperidone and cerebrovascular events [letter]. 141
- Brand F** see **Cano A**
- Cano A, Scaturro DJ, Sprafkin RP, Lantinga LJ, Fiese BH, Brand F.** Family support, self-rated health, and psychological distress. 111–117
- Cano M** see **Ortega P**
- Caples H** see **Felker BL**
- Carney CP** see **Rushing JM**
- Carrigan CG, Lynch DJ.** Managing suicide attempts: guidelines for the primary care physician. 169–176
- Chaney EF** see **Felker BL; Kanter JW**
- Culpepper L.** Depression: we've come a long way! [editorial] 151–152
- Culpepper L.** Evidence for using atypical antipsychotics in mood and anxiety disorders. Suppl 3, 27–32
- Culpepper L.** Five years old and growing [editorial]. 4–5
- Culpepper L, Rakel RE.** Role of atypical antipsychotics in depression in primary care. Suppl 3, 33–37
- Dansky BS** see **Gill JM**
- Detke MJ** see **Mallinckrodt CH**
- Díez T** see **Ortega P**
- Epler AJ** see **Kanter JW**
- Felker BL, Hedrick SC, Chaney EF, Liu C-F, Heagerty P, Caples H, Lin P, Katon W.** Identifying depressed patients with a high risk of comorbid anxiety in primary care. 104–110
- Felker B** see **Kanter JW**
- Fiese BH** see **Cano A**
- Findley JK, Sanders KB, Groves JE.** Role of psychiatry in the management of acute trauma surgery patients. 195–200
- Findling RL.** Dosing of atypical antipsychotics in children and adolescents. Suppl 6, 10–13
- Findling RL.** Treatment of aggression in children. Suppl 6, 5–9
- Forester BP, Oxman TE.** Measures to assess the noncognitive symptoms of dementia in the primary care setting. 158–163
- Freeman EW, Sondheimer SJ.** Premenstrual dysphoric disorder: recognition and treatment. 30–39
- Geldmacher DS.** Long-term cholinesterase inhibitor therapy for Alzheimer's disease: practical considerations for the primary care physician. 251–259
- Gill JM, Dansky BS.** Use of an electronic medical record to facilitate screening for depression in primary care. 125–130
- Goldstein DJ** see **Mallinckrodt CH**
- Gorski E, Willis KC.** Pilot study examining the relationship between patients' complaints and scores on the Hirschfeld Mood Disorder Questionnaire. 201–204
- Graham G** see **Heinrich TW**
- Graves JC.** Review of Taylor D, Paton C (eds): *Case Studies in Psychopharmacology: The Use of Drugs in Psychiatry, 2nd ed.* 142
- Gray KM, Schuyler D.** Conquering an unmasked social phobia [PSYCHOTHERAPY CASEBOOK]. 137–138
- Greenberg DB.** Preventing delirium at the end of life: lessons from recent research. 62–67
- Groves JE** see **Findley JK**
- Hay DP** see **Kabinoff GS**
- Heagerty P** see **Felker BL; Kanter JW**
- Healey KM** see **Kabinoff GS**
- Hedrick SC** see **Felker BL; Kanter JW**
- Heinrich TW, Graham G.** Hypothyroidism presenting as psychosis: myxedema madness revisited. 260–266
- Huffman JC, Stern TA.** Assessment of the awake but unresponsive patient [ROUNDS IN THE GENERAL HOSPITAL]. 227–231
- Huffman JC, Stern TA.** Capacity decisions in the general hospital: when can you refuse to follow a person's wishes? [ROUNDS IN THE GENERAL HOSPITAL]. 177–181
- Huffman JC, Stern TA.** Compassionate care of the terminally ill [ROUNDS IN THE GENERAL HOSPITAL]. 131–136
- Huffman JC, Stern TA.** Disulfiram use in an elderly man with alcoholism and heart disease: a discussion [ROUNDS IN THE GENERAL HOSPITAL]. 41–44
- Huffman JC, Stern TA.** Poststroke neuropsychiatric symptoms and pseudoseizures: a discussion [ROUNDS IN THE GENERAL HOSPITAL]. 85–88
- Huffman JC, Stern TA.** QTc prolongation and the use of antipsychotics: a case discussion [ROUNDS IN THE GENERAL HOSPITAL]. 278–281
- Jones LE** see **Rushing JM**
- Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP.** Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. 6–14
- Kanter JW, Epler AJ, Chaney EF, Liu C-F, Heagerty P, Lin P, Felker B, Hedrick SC.** Comparison of 3 depression screening methods and provider referral in a veterans affairs primary care clinic. 245–250
- Katon W** see **Felker BL**
- Kroenke K.** Interface between physical and psychological symptoms. Suppl 7, 11–18
- Lantinga LJ** see **Cano A**
- Leo RJ.** Reply to Wohlreich MM: Role of duloxetine in the treatment of depression and associated painful physical symptoms [letter]. 287–288
- Leo RJ, Barkin RL.** Antidepressant use in chronic pain management: is there evidence of a role for duloxetine? 118–123
- Lieberman JA III.** History of the use of antidepressants in primary care. Suppl 7, 6–10
- Lieberman JA III.** Introduction. Using atypical antipsychotics in primary care, 2: special populations. Suppl 6, 3–4
- Lieberman JA III.** Use of antipsychotics in primary care. Suppl 3, 3–8
- Lin P** see **Felker BL; Kanter JW**
- Liu C-F** see **Felker BL; Kanter JW**
- Lu Y** see **Mallinckrodt CH**
- Lynch DJ** see **Carrigan CG; Nagel RW**
- Maletic V.** Review of Frances A, Ross R: *DSM-IV-TR Case Studies: A Clinical Guide to Differential Diagnosis*. 50
- Mallin R.** Review of Johnson SL: *Therapist's Guide to Substance Abuse Intervention*. 289
- Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV.** Duloxetine: a new treatment for the emotional and physical symptoms of depression. 19–29
- Marder SR.** Evidence for using atypical antipsychotics in psychosis. Suppl 3, 22–26
- McConathy J, Owens MJ.** Stereochemistry in drug action. 70–73
- McGrady A** see **Nagel RW**
- McGuire HC** see **Kabinoff GS**
- McPherson DS.** Introduction. Emerging evidence in the treatment of depression and chronic pain in primary care: all antidepressants are not created equal. Suppl 7, 3–5

- Mintzer JE.** Managing behavioral dyscontrol related to dementia. Suppl 6, 14–21
- More KF** see **Bobo WY**
- Nagel RW, McGrady A, Lynch DJ, Wahl EF.** Patient-physician relationship and service utilization: preliminary findings. 15–18
- O'Connor MK.** Electronic medical records and depression screening in primary care [letter]. 186
- Ortega P, Cano M, Díez T.** Ziprasidone and QTc prolongation [letter with reply]. 236
- Owens MJ** see **McConathy J**
- Oxman TE** see **Forester BP**
- Pirraglia PA, Stafford RS, Singer DE.** Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. 153–157
- Rakel RE** see **Culpepper L**
- Rushing JM, Jones LE, Carney CP.** Bulimia nervosa: a primary care review. 217–226
- Sanders KB** see **Findley JK**
- Scaturo DJ** see **Cano A**
- Schuyler D.** Brief encounter [PSYCHOTHERAPY CASEBOOK]. 232–233
- Schuyler D.** Reconciliation [PSYCHOTHERAPY CASEBOOK]. 282–283
- Schuyler D.** Remote brief psychotherapy [PSYCHOTHERAPY CASEBOOK]. 182–184
- Schuyler D** see **Gray KM**
- Schwenk TL.** Review of Goldberg D, Murray R (eds): *The Maudsley Handbook of Practical Psychiatry, 4th ed.* 237
- Sharif Z.** Reply to Ortega P: Ziprasidone and QTc prolongation [letter]. 236
- Sharif ZA.** Overview of safety and tolerability of atypical antipsychotics used in primary care. Suppl 3, 14–21
- Sharif ZA.** Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Suppl 6, 22–25
- Shelton RC.** Classification of antidepressants and their clinical implications. Suppl 7, 27–32
- Singer DE** see **Pirraglia PA**
- Sondheimer SJ** see **Freeman EW**
- Sprafkin RP** see **Cano A**
- Stafford RS** see **Pirraglia PA**
- Stahl SM.** Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Suppl 3, 9–13
- States JH, St.Dennis CD.** Chronic sleep disruption and the reexperiencing cluster of posttraumatic stress disorder symptoms are improved by olanzapine: brief review of the literature and a case-based series. 74–79
- St.Dennis CD** see **States JH**
- Stern TA** see **Huffman JC; Worth JL**
- Stovall J.** Review of Edwards J, McGorry PD: *Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services.* 187
- Sussman N.** SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms. Suppl 7, 19–26
- Symons SC.** Binge eating, depression, and cognitive therapy [PSYCHOTHERAPY CASEBOOK]. 45–46
- Toalson PA** see **Kabinoff GS**
- Tran PV** see **Mallinckrodt CH**
- Varon D.** Biweekly cognitive therapy for social phobia [PSYCHOTHERAPY CASEBOOK]. 89–90
- Vieweg WVR.** New generation antipsychotic drugs and QTc interval prolongation. 205–215
- Wahl EF** see **Nagel RW**
- Watkin JG** see **Mallinckrodt CH; Wohlreich MM**
- Willis KC** see **Gorski E**
- Wohlreich MM, Watkin JG.** Role of duloxetine in the treatment of depression and associated painful physical symptoms [letter with reply]. 286–287
- Wolff CG.** Daughter dearest? [DIARY FROM THE FRONT LINES] 91–92
- Wolff CG.** “Have a nice trip, see you next fall?” [DIARY FROM THE FRONT LINES] 284–285
- Wolff CG.** Sexual dysfunction to the rescue [DIARY FROM THE FRONT LINES]. 139–140
- Wolff CG.** Turn your partner, do-si-do! now take your sertraline, cotton-eyed joe! [DIARY FROM THE FRONT LINES] 234–235
- Wolff CG.** “Twin angels” [DIARY FROM THE FRONT LINES]. 185
- Wolff CG.** “What’s that smell?” [DIARY FROM THE FRONT LINES] 47–48
- Worth JL, Stern TA.** Benefits of an outpatient psychiatric teleconsultation unit: results of a 1-year pilot. 80–84